About: Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
Creator	Wei, Wei Wang, Jing Wang, Lu Chen, Xin Liu, Bo Wang, Yanan Shu, Bo Wang, Jin Liu, Wenhua Miao, Xiaoping Wang, S Wang, Z Zhou, Fan Wang, Y Zhang, Ming Cheng, Biao Yang, Chunguang Yao, Zhi Hu, Z Hu, Zhiquan Wang, Shaogang Wang, Zhihua Wu, Shiji Yang, C Cai, Y Cai, Yimin Chen, Wenqiong Deng, Xiongbo Fan, Jiquan Li, Qinglin Liu, Shuanglin Lu, Zequn Niu, Siyuan Tian, Jianbo Xiao, J Xiao, Jun Yang, Qin Yang, Xiang-Ping Zhong, Qiang Yuan, Xianglin Bs, Chen Bs, Niu Bs, Wang Bs, Zhang Phd, Lu Tian, Health Yang, X-P
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: COVID-19 has spread globally. Epidemiological susceptibility to COVID-19 has been reported in patients with cancer. We aimed to systematically characterise clinical features and determine risk factors of COVID-19 disease severity for patients with cancer and COVID-19. METHODS: In this multicentre, retrospective, cohort study, we included all adult patients (aged ≥18 years) with any type of malignant solid tumours and haematological malignancy who were admitted to nine hospitals in Wuhan, China, with laboratory-confirmed COVID-19 between Jan 13 and March 18, 2020. Enrolled patients were statistically matched (2:1) with patients admitted with COVID-19 who did not have cancer with propensity score on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, illness severity, and clinical interventions were compared between patients with COVID-19 with or without cancer as well as between patients with cancer with non-severe or severe COVID-19. COVID-19 disease severity was defined on admission on the basis of the WHO guidelines. Univariable and multivariable logistic regression, adjusted for age, sex, comorbidities, cancer type, tumour stage, and antitumour treatments, were used to explore risk factors associated with COVID-19 disease severity. This study was registered in the Chinese Clinical Trial Register, ChiCTR2000030807. FINDINGS: Between Jan 13 and March 18, 2020, 13 077 patients with COVID-19 were admitted to the nine hospitals in Wuhan and 232 patients with cancer and 519 statistically matched patients without cancer were enrolled. Median follow-up was 29 days (IQR 22–38) in patients with cancer and 27 days (20–35) in patients without cancer. Patients with cancer were more likely to have severe COVID-19 than patients without cancer (148 [64%] of 232 vs 166 [32%] of 519; odds ratio [OR] 3·61 [95% CI 2·59–5·04]; p<0·0001). Risk factors previously reported in patients without cancer, such as older age; elevated interleukin 6, procalcitonin, and D-dimer; and reduced lymphocytes were validated in patients with cancer. We also identified advanced tumour stage (OR 2·60, 95% CI 1·05–6·43; p=0·039), elevated tumour necrosis factor α (1·22, 1·01–1·47; p=0·037), elevated N-terminal pro-B-type natriuretic peptide (1·65, 1·03–2·78; p=0·032), reduced CD4+ T cells (0·84, 0·71–0·98; p=0·031), and reduced albumin–globulin ratio (0·12, 0·02–0·77; p=0·024) as risk factors of COVID-19 severity in patients with cancer. INTERPRETATION: Patients with cancer and COVID-19 were more likely to deteriorate into severe illness than those without cancer. The risk factors identified here could be helpful for early clinical surveillance of disease progression in patients with cancer who present with COVID-19. FUNDING: China National Natural Science Foundation.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1016/s1470-2045(20)30309-0
bibo:pmid	32479790
has license	no-cc
sha1sum (hex)	0ae2b8035050ca7f5150c2e869ff45492e1508f0
schema:url	https://doi.org/10.1016/s1470-2045%2820%2930309-0
resource representing a document's title	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
has PubMed Central identifier	PMC7259911
has PubMed identifier	32479790
schema:publication	Lancet Oncol
resource representing a document's body	covid:0ae2b8035050ca7f5150c2e869ff45492e1508f0#body_text
is schema:about of	named entity 'cancer' named entity 'determine' named entity 'COVID-19' named entity 'COVID-19' named entity 'globally' named entity 'cancer' named entity 'SPSS' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'older age' named entity 'COVID-19' named entity 'tumour stage' named entity 'Hypertension' named entity 'Tongji Medical College' named entity 'organ damage' named entity 'IL-6' named entity 'lymphocytes' named entity 'IL-1β' named entity 'inflammation' named entity 'globulin' named entity 'risk factors' named entity 'albumin' named entity 'globulin' named entity 'Wuhan' named entity 'pro-inflammatory cytokines' named entity 'COVID-19' named entity 'tumour' named entity 'COVID' named entity 'TNF-α' named entity 'tocilizumab' named entity 'older age' named entity 'malignant' named entity 'cytotoxic T cells' named entity 'dyspnoea' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software